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years. The data bases used were PubMed/MEDLINE and
EMBASE. Also, Spanish magazines not indexed in MEDLINE
were reviewed. A review about growth of cost-utility published
studies and other about threshold of the health technology in
Spain, both were included too. Abstracts of Medtronic therapies
and other health technology and devices enterprises were
reviewed. Costs were in euros of the year 2007. RESULTS:
Thirty-one studies with cost/QALY ratio were identiﬁed, 22 of
drug therapies and 8 of diagnostic and therapeutic devices. Cost/
QALY ratio of drug therapies oscillated between -€25.937
(Dasatinib in patients resistant to imatimab in myeloid leukemia)
and €72,583 (Pneumococcal vaccine vs. no vaccine in patients
5–24 years). In diagnostic and therapeutic devices cost/QALY
ratio was between -€30,664 (DES vs. BMS) and €34.389 (Sub-
thalamus stimulation vs. conventional medical therapy in
advanced Parkinson). CONCLUSIONS: In the reviewed studies,
diagnostic and therapeutic devices were cost-effective with a cost
per QALY relation under or near the efﬁciency threshold usually
accepted in Spain. This relation in some cases was lower than
drug therapies used in the usual clinical practice.
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OBJECTIVES: To determine if there are regional market access
inequalities for innovative antineoplastic and immunomodula-
tory drugs (AID) in Spain. METHODS: All new AIDs introduced
in Spain were identiﬁed between 2002 and 2007. AID units
adjusted by population and region were analyzed by means of the
IMS Health Databases: EMF, EMH, and EMHEMF. The time
horizon considered was 12 months prior to September 2007
(MAT 09/07). Regions were the minimal geographic unit allowed
by the databases in order to ensure the representativeness of the
data (I: Aragon, Catalonia, Balearic Islands; II: Valencia, Murcia;
III: Andalusia, Canary Islands; IV: Castile la Mancha, Extrema-
dura, Madrid; V: Asturias, Castile-Leon, Galicia, Navarra,
Basque Country, La Rioja, Cantabria). RESULTS: In Spain,
between January 2002 and October 2007, 16 AIDs were
approved. For methodological limitations only ten drugs were
analyzed: three hospital diagnostic (HD) (imatinib, erlotinib y
sorafenib), six hospital use (H) (alemtuzumab, bortezomib, beva-
cizumab, cetuximab, ibritumomab and pemetrexed) and 1
medical prescription (fulvestrant). HD drugs showed high vari-
ability in units per in-habitant between regions. Erlotinib pre-
sented a 27.7% Standard Deviation (SD) between zones,
concentrating the 69% in zone I. The 31% was distributed
uniformly in the other regions. Imatinib presented a 25% SD,
zone I and V covered the 53.6% and 40.3% of the units
respectively. Sorafenil presented less geographic variation
(SD = 10.1%). Regional differences between hospital drugs were
smaller. SD oscillated between 9.8% (bevacizumab) and 5.3%
(pemetrexed). Zone II presented the highest market share. When
analysing fulvestrant, zones I and V concentrated the 60.9% of
the units and the inter-regional SD was 13.6%. CONCLU-
SIONS: There are important regional inequalities in the number
of units per in-habitant sold for new AIDs. Zones I and V
presented the highest market share whereas in the other zones
market access is highly restricted.
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OBJECTIVES: On the February 15, 2007 new forms of
co-payment were introduced in Hungary: visit fee (300 HUF/
visit) in the outpatient care and hospital daily fee (300 HUF/day)
in the inpatient care. The aim of this study is to analyze the effect
of the introduction of hospital daily fee on the number of inpa-
tient admissions to acute care hospital wards in Hungary
METHODS: The data derive from the ﬁnancial database of the
National Health Insurance Fund Administration (OEP) of
Hungary covering the period of 2006–2008. We analyzed the
number of admissions during a 10 months period before (from
March 2006 to January 2007) and after (from March 2007 to
January 2008) the introduction of daily fee. Data from February
2007 were omitted. RESULTS: During the 10 months period
before the introduction of hospital daily fee the total number of
admissions was 2,285,011, while during the 10 months period
after the introduction of daily fee it decreased to 1.940.880. The
average monthly number of admissions was 207,728 before and
176,444 after the introduction of daily fee. This represents a
15.1% decrease in the number of acute care admissions. CON-
CLUSIONS: The introduction of hospital daily fee in the Hun-
garian inpatient care resulted in a signiﬁcant decrease of acute
inpatient care admissions. However we do not have information
whether admissions failed to be realized were really unnecessary
or not. Other elements of the health care reforms could have also
inﬂuenced the number of admissions.
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OBJECTIVES: On the 15th of February 2007 new forms of
co-payment were introduced in Hungary: visit fee (300 HUF/
visit) in the outpatient care and hospital daily fee (300 HUF/day)
in the inpatient care. The aim of this study is to analyze the effect
of the introduction of visit fee on the number of patient-visits to
outpatient care departments in Hungary. METHODS: The data
derive from the ﬁnancial database of the National Health Insur-
ance Fund Administration (OEP) of Hungary covering the period
of 2006–2008. We analyzed the number of patient visits during
a 10 months period before (from March 2006 to January 2007)
and after (from March 2007 to January 2008) the introduction
of visit fee. Data from February 2007 were omitted. RESULTS:
During the 10 months period before the introduction of visit fee
the total number of visits was 64,309,067, while during the 10
months period after the introduction of visit fee it decreased to
51.927.150. The average monthly number of outpatient visits
was 5,846,279 before and 4,720,650 after the introduction of
visit fee. This represents a 19.3% decrease in the number of
outpatient visits. CONCLUSIONS: The introduction of visit fee
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in the Hungarian outpatient care resulted in a signiﬁcant decrease
of outpatient visits. However we do not have information
whether visits failed to be realized were really unnecessary or not.
Other elements of the health care reforms could have also inﬂu-
enced the number of outpatient visits.
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OBJECTIVES: The hospital bed capacities have a special impor-
tance during health care reforms. Many health care reforms
aimed to reduce the number of hospital beds. The aim of this
study is to analyze and compare the hospital bed capacities of old
and new member states of the European Union before and after
the social changes in 1990. METHODS: The data were derived
from the Health for All database of the World Health Organiza-
tion (WHO) as of November 2007 covering the period 1980–
2005. We compared the total number of hospital beds per
100,000 between the old (EU-15) and the new (EU-12, members
since 2004 or 2007) member states of the European Union.
RESULTS: In the early 1980’s the number of hospital beds per
100.000 was signiﬁcantly higher in the old (EU-15) member
states (around 900 beds) compared to new (EU-12) member
states (around 850 beds). In 1990, this trend turned over result-
ing in a higher number of hospital beds per 100,000 in the new
member states (868 beds) compared to old member states (801
beds). By 2005 the gap between old (564 beds per 100,000) and
new (640 beds per 100,000) member states’ hospital bed capaci-
ties became wider. CONCLUSIONS: Between 1980 and 2005
the number of hospital beds per 100,000 became higher in new
(EU-12) member states of the European Union compared to old
member states. The gap between old and new member states had
been widening by 2005. The social and political changes in
Eastern Europe in 1990 did not managed to close the gap of
hospital bed capacities between old and new member states.
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OBJECTIVES: The aim of this study is to analyze the attendance
of insurants registered with general practitioners (GP) in county
Baranya during the one year existence of visit fee. METHODS:
The analysis is based on the monthly reports (B300 form) from
general practitioners. The study covered the period between
March 2007 and February 2008. The analysis shows the atten-
dance of insurants registered with any GP in county Baranya.
The number of registered patients is as of February 2008.
RESULTS: The number of insurants registered with GPs in
county Baranya was 387,441 persons, who had 2,458,765 atten-
dances during one year in any of the 298 GP praxis. The average
number of attendance is 6.3 per insurant, which are stratiﬁed
according to the followings: Sex: males 5.5, women 6.8;
Age-groups: 0–1 y:14.8, 2–7 y:10, 8–14 y:5.6, 15–19 y:4.9,
20–29 y:2.8, 30–39 y:3.1, 40–49 y:4.7, 50–59 y:7, 60–69 y:8.5,
70–79 y:10.8, 80 y–:11.5 Number of settlements: 1 settlement 6,
2 settlements 6.6, 3 settlements 6.9, 4 settlements 7, 5 settlements
6.6; Number of GP ofﬁce: 1 ofﬁce 5.9, 2 ofﬁces 6.4, 3 ofﬁces 7.1,
4 ofﬁces 6.8, 5 ofﬁces 6.8; Type of settlement: city 6.1, village 6.6;
Total number of attendances on week-days:—On monthly base:
January 11,519, February 10,729, March 10,335, April 9,655,
May 9,703, June 8,779, July 7,661, August 7,638, September
9,310, October 9,294, November 10,492, December 9,590
persons;—According to week-days: Monday 11,457, Tuesday
10,291, Wednesday 9,931, Thursday 9,617, Friday 8,631, Sat-
urday (if workday) 5,645 persons. CONCLUSIONS: The utili-
zation of GPs praxis is the highest on the ﬁrst workday on the
week, in winter months, in younger age-groups (0–1 year) and
for women. As the number of settlements and ofﬁces increases,
the attendance slightly increased also, in harmony with the
higher utilization in villages. In the background we can assume
the closer the GP the higher the utilization.
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OBJECTIVES: The Academy of Managed Care Pharmacy
(AMCP) Format for Formulary Submission (v2.1) is a set of
guidelines intended to standardize the clinical and economic
information submitted by drug companies to health plans for
formulary determination. We examined familiarity with, and use
of, the Format among pharmacy directors at U.S. health plans
nationwide. METHODS: We obtained a list of U.S. health plans
providing prescription drug coverage from the HealthLeaders-
InterStudy database as of July 2006. After excluding local afﬁli-
ates of national or regional plans, there were 257 plans in the
sample. Data were collected from May to November 2007
through self-administered questionnaires sent to pharmacy direc-
tors or formulary managers. RESULTS: A total of 135 of 257
questionnaires were completed (response rate = 52.5%). Respon-
dents represented plans with over 125 million covered lives (74%
of covered lives accounted for by contacted plans). Most health
plans maintain formulary decision-making responsibility, though
some (especially at smaller plans) use input from pharmaceutical
beneﬁt managers (PBMs) to guide formulary decisions. 3/5 of all
respondents and almost 90% of those at large plans (>500,000
covered lives) were extremely familiar or familiar with the
Format. Approximately 36% of all pharmacy directors (56% of
those at large plans) request information from drug ﬁrms in an
AMCP Format structure. With regard to safety and efﬁcacy for
labeled use, health plans were more likely to perceive informa-
tion provided in Format-compatible dossiers to be complete and
clear or easy to understand than information in other presenta-
tions. Information related to off-label use and costs and beneﬁts
was frequently perceived by plans to be incomplete, lacking in
clarity, and biased, regardless of whether it was in a Format-
compatible presentation. CONCLUSIONS: Familiarity with the
AMCP Format is high among pharmacy directors at U.S. health
plans. Adoption of the Format has increased steadily over time,
especially among large plans.
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